Evidence map›Paper›PMID 33148792›Full record

ArticleJournal of virology2021

Dual Pathways of Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Trafficking Modulate the Selective Exclusion of Uncleaved Oligomers from Virions.

Shijian Zhang, Hanh T Nguyen, Haitao Ding, Jia Wang, Shitao Zou, Lihong Liu, Debjani Guha, Dana Gabuzda, David D Ho, John C Kappes and 1 more

Open access · greenAbstract read
In one paragraph

Article in Journal of virology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
3.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 40 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Cell-cell communication: new insights and clinical implications.Signal transduction and targeted therapy · 2024
    Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Shijian Zhang *Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Hanh T Nguyen *Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Haitao DingDepartment of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Jia WangDepartment of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Shitao ZouDepartment of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Lihong LiuAaron Diamond AIDS Research Center, Columbia University Vagellos College of Physicians and Surgeons, New York, New York, USA.
Debjani GuhaDepartment of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Dana GabuzdaDepartment of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
David D HoAaron Diamond AIDS Research Center, Columbia University Vagellos College of Physicians and Surgeons, New York, New York, USA.
John C KappesDepartment of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Joseph SodroskiDepartment of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA joseph_sodroski@dfci.harvard.edu.ORCID 0000-0002-9750-1615
Harvard University · USDana-Farber Cancer Institute · USAaron Diamond AIDS Research Center · USUniversity of Alabama at Birmingham · US

Funding

Virology CoreP30AI027767 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Paul A. Goepfert · 1988 to 2026
$84.1M
Understanding Envelope Function in HIV-1 Infection: The Design, Synthesis and Validation of Small Molecule HIV-1 Env InhibitorsP01GM056550 · NIGMS · UNIVERSITY OF PENNSYLVANIA · PI HENDRICKSON, WAYNE A. · 1997 to 2018
$31.2M
Understanding Envelope Function in HIV-1 Infection: The Design, Synthesis and Validation of Small Molecule HIV-1 Env InhibitorsP01AI150471 · NIAID · DREXEL UNIVERSITY · PI CHAIKEN, IRWIN M, MOTHES, WALTHER H · 2019 to 2022
$7.8M
Conformational Landscape of the HIV-1 Envelope GlycoproteinsR01AI124982 · NIAID · DANA-FARBER CANCER INST · PI SODROSKI, JOSEPH G · 2016 to 2025
$6.7M
Generating Native Env Glycosylation in HIV Vaccine CandidatesR01AI125093 · NIAID · UNIVERSITY OF KANSAS LAWRENCE · PI DESAIRE, HEATHER R · 2016 to 2019
$2.7M
Enrichment of the State-1 Conformation of the HIV-1 Envelope GlycoproteinR01AI145547 · NIAID · DANA-FARBER CANCER INST · PI SODROSKI, JOSEPH G · 2019 to 2021
$2.2M
Reducing viral reservoirs by opening HIV-1 Env to antibody attackR33AI129017 · NIAID · DANA-FARBER CANCER INST · PI SODROSKI, JOSEPH G · 2019 to 2021
$1.6M
CNS Viral Escape in HIV-infected AdultsR56MH115853 · NIMH · DANA-FARBER CANCER INST · PI GABUZDA, DANA H. · 2019 to 2019
$583k
NIAID NIH HHS P01 AI150471NIAID NIH HHS P30 AI027767NIAID NIH HHS R01 AI124982NIAID NIH HHS R01 AI125093NIAID NIH HHS R01 AI145547NIAID NIH HHS R33 AI129017NIGMS NIH HHS P01 GM056550NIMH NIH HHS R56 MH115853
6 · The paper itself

Abstract

The human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein (Env) trimer is transported through the secretory pathway to the infected cell surface and onto virion particles. In the Golgi, the gp160 Env precursor is modified by complex sugars and proteolytically cleaved to produce the mature functional Env trimer, which resists antibody neutralization. We observed mostly uncleaved gp160 and smaller amounts of cleaved gp120 and gp41 Envs on the surface of HIV-1-infected or Env-expressing cells; however, cleaved Envs were relatively enriched in virions and virus-like particles (VLPs). This relative enrichment of cleaved Env in VLPs was observed for wild-type Envs, for Envs lacking the cytoplasmic tail, and for CD4-independent, conformationally flexible Envs. On the cell surface, we identified three distinct populations of Envs: (i) the cleaved Env was transported through the Golgi, was modified by complex glycans, formed trimers that cross-linked efficiently, and was recognized by broadly neutralizing antibodies; (ii) a small fraction of Env modified by complex carbohydrates escaped cleavage in the Golgi; and (iii) the larger population of uncleaved Env lacked complex carbohydrates, cross-linked into diverse oligomeric forms, and was recognized by poorly neutralizing antibodies. This last group of more "open" Env oligomers reached the cell surface in the presence of brefeldin A, apparently bypassing the Golgi apparatus. Relative to Envs transported through the Golgi, these uncleaved Envs were counterselected for virion incorporation. By employing two pathways for Env transport to the surface of infected cells, HIV-1 can misdirect host antibody responses toward conformationally flexible, uncleaved Env without compromising virus infectivity.

Indexed as

Protein MultimerizationA549 Cellsenv Gene Products, Human Immunodeficiency VirusHIV-1HIV AntibodiesHIV InfectionsHumansProtein BindingProtein ConformationProtein TransportVirionenv Gene Products, Human Immunodeficiency VirusHIV Antibodiesantibodycell surfacecleavageEnvGolgi bypasstraffickingvirion incorporation

Identifiers

PMID33148792
PMCPMC7925103
OpenAlexW3097505790

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.